Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 1
2(28.6%)
7Total
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02665364Phase 2Terminated

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

Role: lead

NCT02980198Phase 2Withdrawn

Study of IFN-K in Dermatomyositis

Role: lead

NCT01911234Phase 2Completed

Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis

Role: lead

NCT01058343Phase 1Completed

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Role: lead

NCT01291810Phase 2Completed

Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients

Role: lead

NCT01040715Phase 2Completed

Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists

Role: lead

NCT00808262Phase 1Completed

Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

Role: lead

All 7 trials loaded